Increasing Awareness of Papillomaviruses and Their Association with Human Diseases
Men's Health Journal,
Vol. 3 No. 1 (2019),
13 April 2019
,
Page e15
https://doi.org/10.22037/mhj.v3i1.33119
Abstract
The papillomavirus family is known to be responsible for a quarter of virus-related cancers worldwide. High-risk types are the causative agents of anogenital, cervical and various cancers of the mouth, throat, intestines, vagina, penis and anus. Cervical cancer and various other malignancies induced by papillomaviruses are a global health problem, and the growing prevalence of these diseases indicates the need to increase awareness of this viral family. In this review, published articles during 2001-2020 were searched using keywords such as Papillomavirus, Cervical Cancer and Papilloma Vaccine. Our review represents the results of the association of high-risk HPV serotypes with many malignancies in human. Furthermore, issues such as HPV vaccination, cervical cancer screening, and other preventive programs worldwide are discussed.
How to Cite
Divbandi, M., Tabarraei, A., & Nematollahi, S. (2020). Increasing Awareness of Papillomaviruses and Their Association with Human Diseases. Men’s Health Journal, 3(1), e15. https://doi.org/10.22037/mhj.v3i1.33119
References
1. Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, et al. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. Journal of virology. 2009;83(15):7690-705.
2. Lowy DR. History of papillomavirus research. The Papillomaviruses: Springer; 2007. p. 13-28.
3. Prado JC, Calleja-Macias IE, Bernard H-U, Kalantari M, Macay SA, Allan B, et al. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology. 2005;340(1):95-104.
4. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. JNCI: Journal of the National Cancer Institute. 2015;107(6).
5. Alijanpour Aghamolkei M, Tabarraei A, Moradi A, Sadeghi F, Yahyapour Y. Detection of Human Papillomavirus in Osophageal Squamous Cell Carcinoma samples in Mazandaran Province, Iran. International Journal of Molecular and Clinical Microbiology. 2017;7(1):741-7.
6. Bashaw AA, Leggatt GR, Chandra J, Tuong ZK, Frazer IH. Modulation of antigen presenting cell functions during chronic HPV infection. Papillomavirus Research. 2017;4:58-65.
7. Bordignon V, Di Domenico EG, Trento E, D’Agosto G, Cavallo I, Pontone M, et al. How human papillomavirus replication and immune evasion strategies take advantage of the host DNA damage repair machinery. Viruses. 2017;9(12):390.
8. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best practice & research Clinical obstetrics & gynaecology. 2018;47:14-26.
9. Munoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International journal of cancer. 2004;111(2):278-85.
10. Boulet G, Horvath C, Broeck DV, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. The international journal of biochemistry & cell biology. 2007;39(11):2006-11.
11. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses. 2017;9(8):229.
12. Chen Y, Liu Y, Zhang G, Wang A, Dong Z, Qi Y, et al. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. Virus research. 2016;220:97-103.
13. DiGiuseppe S, Bienkowska-Haba M, Guion LG, Keiffer TR, Sapp M. Human papillomavirus major capsid protein L1 remains associated with the incoming viral genome throughout the entry process. Journal of virology. 2017;91(16).
14. Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clinical science. 2017;131(17):2201-21.
15. Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. The Journal of infectious diseases. 2013;207(8):1286-94.
16. Fu T-cJ, Hughes JP, Feng Q, Hulbert A, Hawes SE, Xi LF, et al. Epidemiology of Human Papillomavirus (HPV) Detected in the Oral Cavity and Fingernails of Mid-Adult Women. Sexually transmitted diseases. 2015;42(12):677.
17. Chan PK, Picconi MA, Cheung TH, Giovannelli L, Park JS. Laboratory and clinical aspects of human papillomavirus testing. Critical reviews in clinical laboratory sciences. 2012;49(4):117-36.
18. Sohrabi A, Rahnamaye Farzami M, Mirab Samiee S, Modarresi MH. An overview on papillomaviruses as the main cause of cervical cancer. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2015;18(145):14-25.
19. Papillomavirus H. Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-07-27) I. Key data on HPV and HPV-related cancers. 2017;2017:6-7.
20. Liu L, Ying C, Zhao Z, Sui L, Zhang X, Qian C, et al. Identification of reliable biomarkers of human papillomavirus 16 methylation in cervical lesions based on integration status using high-resolution melting analysis. Clinical epigenetics. 2018;10(1):1-12.
21. Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. The Journal of Immunology. 2014;192(9):4007-11.
22. Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong Z-Y, Xiao W, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. Journal of Clinical Oncology. 2018;36(3):262.
23. Gillison ML, Broutian T, Pickard RK, Tong Z-y, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. Jama. 2012;307(7):693-703.
24. Buckley B HN, Maayan N, Marshall R, Lutje V, Soares-Weiser K. Anogenital warts: incidence, prevalence, self-reported history and quality of life. London, UK: Cochrane Response. 2016.
25. Ponder BA. Cancer genetics. Nature. 2001;411(6835):336-41.
26. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus genes. 2010;40(1):1-13.
27. Xue J, Vesper BJ, Radosevich JA. Human Papillomavirus: A Brief Overview. HPV and Cancer: Springer; 2012. p. 1-15.
28. Alp AG. Genomic organization and proteins of human papillomavirus. Mikrobiyoloji bulteni. 2012;46(3):507.
29. Bosch FX, Lorincz A, Muñoz N, Meijer C, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of clinical pathology. 2002;55(4):244-65.
30. Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001;20(54):7888-98.
31. Huh K, Zhou X, Hayakawa H, Cho J-Y, Libermann TA, Jin J, et al. Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Cullin 2 Ubiquitin Ligase Complex, Which Contributes to Degradation of the Retinoblastoma Tumor Suppressor. Journal of Virology. 2007;81(18):9737-47.
32. Jabbar SF, Park S, Schweizer J, Berard-Bergery M, Pitot HC, Lee D, et al. Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein. Cancer research. 2012;72(16):4008-16.
33. Miller J, Dakic A, Chen R, Palechor-Ceron N, Dai Y, Kallakury B, et al. HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytes. PLoS Pathog. 2013;9(4):e1003284.
34. Scheffner M, Whitaker NJ, editors. Human papillomavirus-induced carcinogenesis and the ubiquitin–proteasome system. Seminars in cancer biology; 2003: Elsevier.
35. Rasouli E, Shahnavaz Z, Basirun WJ, Rezayi M, Avan A, Ghayour-Mobarhan M, et al. Advancements in electrochemical DNA sensor for detection of human papilloma virus-A review. Analytical biochemistry. 2018;556:136-44.
36. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Meerten ELvP, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. Journal of translational medicine. 2013;11(1):88.
37. Murall CL, Reyné B, Selinger C, Bernat C, Boué V, Grasset S, et al. HPV cervical infections and serological status in vaccinated and unvaccinated women. Vaccine. 2020.
38. Del Prete R, Ronga L, Magrone R, Addati G, Abbasciano A, Di Carlo D, et al. Epidemiological evaluation of human papillomavirus genotypes and their associations in multiple infections. Epidemiology & Infection. 2019;147.
39. Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, et al. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. Journal of biomedical science. 2014;21(1):69.
40. Schiffman M, Doorbar J, Wentzensen N, De Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nature reviews Disease primers. 2016;2(1):1-20.
41. Castle PE, Eaton B, Reid J, Getman D, Dockter J. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology. Journal of clinical microbiology. 2015;53(4):1277-81.
42. Nobbenhuis M, Meijer C, Van Den Brule A, Rozendaal L, Voorhorst F, Risse E, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. British journal of cancer. 2001;84(6):796-801.
43. de Sanjose S, Holme F. What is needed now for successful scale-up of screening? Papillomavirus Research. 2019;7:173-5.
44. Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. The lancet oncology. 2011;12(11):1023-31.
45. Ewaisha R, Panicker G, Maranian P, Unger ER, Anderson KS. Serum immune profiling for early detection of cervical disease. Theranostics. 2017;7(16):3814.
46. Sohrabi A, Mirab-Samiee S, Modarresi MH, Izadimood N, Azadmanesh K, Rahnamaye-Farzami M. Development of in-house multiplex real time PCR for human papillomavirus genotyping in Iranian women with cervical cancer and cervical intraepithelial neoplasia. Asian Pac J Cancer Prev. 2014;15(15):6257-61.
47. Phillips S, Garland SM, Tan JH, Quinn MA, Tabrizi SN. Comparison of the Roche Cobas® 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for detection of high-risk human papillomavirus genotypes in women undergoing treatment for cervical dysplasia. Journal of Clinical Virology. 2015;62:63-5.
48. Lie A, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecologic oncology. 2005;97(3):908-15.
49. Pitts MK, Fox C, Willis J, Anderson J. What do gay men know about human papillomavirus? Australian gay men's knowledge and experience of anal cancer screening and human papillomavirus. Sexually transmitted diseases. 2007;34(3):170-3.
50. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 2014;63(5):1-30.
51. Fait T, Dvořák V, Pilka R. Nine-valent HPV vaccine-new generation of HPV vaccine. Ceska gynekologie. 2015;80(6):397-400.
52. Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, et al. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine. 2017;35(35):4637-45.
53. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert opinion on drug safety. 2015;14(5):697-712.
54. Bouvret P, Mougin C, Pretet J, Meurisse A, Bonnetain F, Fiteni F. Practices and attitudes regarding HPV vaccination among general practitioners from Besançon. Journal de gynecologie, obstetrique et biologie de la reproduction. 2016;45(8):972-8.
55. Oshman LD, Davis AM. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). jama. 2020;323(5):468-9.
56. Ferley J, Bray F, Pisani P, Parkin D. Globocan 2002: Cancer incidence, mortality and prevalence worldwide, IARC Cancerbase. No 5, Version 2.0. Lyon: IARC Press; 2004.
57. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama. 2013;309(17):1793-802.
58. Szarewski A. HPV vaccination and cervical cancer. Current oncology reports. 2012;14(6):559-67.
59. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute. 2004;96(8):604-15.
60. Organization WH. Use of cryotherapy for cervical intraepithelial neoplasia. WHO Geneva; 2011.
61. Organization WH. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention: World Health Organization; 2013.
62. Grabowska AK, Kaufmann AM, Riemer AB. Identification of promiscuous HPV16‐derived T helper cell epitopes for therapeutic HPV vaccine design. International journal of cancer. 2015;136(1):212-24.
63. López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Computational and structural biotechnology journal. 2016;14:58-68.
64. Kim HJ, Kim SY, Lim SJ, Kim JY, Lee SJ, Kim H-J. One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein expression and purification. 2010;70(1):68-74.
65. Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. New biotechnology. 2017;39:174-80.
66. Agency EM. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. 2016.
67. Control CfD, Prevention. Human papillomavirus (HPV) ACIP vaccine recommendations. Series Retrieved from https://www cdc gov/vaccines/hcp/acip-recs/vacc-specific/hpv html. 2016.
68. Cancer ICoESoC. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiology Biomarkers & Prevention. 2009;18(4):1060.
69. Castillejo MM, Beceiro BB, Villanueva MN, Peguera PC, Baquerano MM. Estrategias de prevención del cáncer. Aten Primaria. 2007;39(Supl 3):47-66.
70. Family A. New Findings on Contraceptives. Health. 2008.
71. Al Moustafa A-E, Kassab A, Darnel A, Yasmeen A. High-risk HPV/ErbB-2 interaction on E-cadherin/catenin regulation in human carcinogenesis. Current pharmaceutical design. 2008;14(22):2159-72.
72. Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre‐cancer: Results from the EPIC cohort. International journal of cancer. 2014;135(2):453-66.
73. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. American Journal of Transplantation. 2019;19(11):3202-6.
2. Lowy DR. History of papillomavirus research. The Papillomaviruses: Springer; 2007. p. 13-28.
3. Prado JC, Calleja-Macias IE, Bernard H-U, Kalantari M, Macay SA, Allan B, et al. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology. 2005;340(1):95-104.
4. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. JNCI: Journal of the National Cancer Institute. 2015;107(6).
5. Alijanpour Aghamolkei M, Tabarraei A, Moradi A, Sadeghi F, Yahyapour Y. Detection of Human Papillomavirus in Osophageal Squamous Cell Carcinoma samples in Mazandaran Province, Iran. International Journal of Molecular and Clinical Microbiology. 2017;7(1):741-7.
6. Bashaw AA, Leggatt GR, Chandra J, Tuong ZK, Frazer IH. Modulation of antigen presenting cell functions during chronic HPV infection. Papillomavirus Research. 2017;4:58-65.
7. Bordignon V, Di Domenico EG, Trento E, D’Agosto G, Cavallo I, Pontone M, et al. How human papillomavirus replication and immune evasion strategies take advantage of the host DNA damage repair machinery. Viruses. 2017;9(12):390.
8. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best practice & research Clinical obstetrics & gynaecology. 2018;47:14-26.
9. Munoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International journal of cancer. 2004;111(2):278-85.
10. Boulet G, Horvath C, Broeck DV, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. The international journal of biochemistry & cell biology. 2007;39(11):2006-11.
11. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses. 2017;9(8):229.
12. Chen Y, Liu Y, Zhang G, Wang A, Dong Z, Qi Y, et al. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. Virus research. 2016;220:97-103.
13. DiGiuseppe S, Bienkowska-Haba M, Guion LG, Keiffer TR, Sapp M. Human papillomavirus major capsid protein L1 remains associated with the incoming viral genome throughout the entry process. Journal of virology. 2017;91(16).
14. Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clinical science. 2017;131(17):2201-21.
15. Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. The Journal of infectious diseases. 2013;207(8):1286-94.
16. Fu T-cJ, Hughes JP, Feng Q, Hulbert A, Hawes SE, Xi LF, et al. Epidemiology of Human Papillomavirus (HPV) Detected in the Oral Cavity and Fingernails of Mid-Adult Women. Sexually transmitted diseases. 2015;42(12):677.
17. Chan PK, Picconi MA, Cheung TH, Giovannelli L, Park JS. Laboratory and clinical aspects of human papillomavirus testing. Critical reviews in clinical laboratory sciences. 2012;49(4):117-36.
18. Sohrabi A, Rahnamaye Farzami M, Mirab Samiee S, Modarresi MH. An overview on papillomaviruses as the main cause of cervical cancer. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2015;18(145):14-25.
19. Papillomavirus H. Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-07-27) I. Key data on HPV and HPV-related cancers. 2017;2017:6-7.
20. Liu L, Ying C, Zhao Z, Sui L, Zhang X, Qian C, et al. Identification of reliable biomarkers of human papillomavirus 16 methylation in cervical lesions based on integration status using high-resolution melting analysis. Clinical epigenetics. 2018;10(1):1-12.
21. Frazer IH. Development and implementation of papillomavirus prophylactic vaccines. The Journal of Immunology. 2014;192(9):4007-11.
22. Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong Z-Y, Xiao W, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. Journal of Clinical Oncology. 2018;36(3):262.
23. Gillison ML, Broutian T, Pickard RK, Tong Z-y, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. Jama. 2012;307(7):693-703.
24. Buckley B HN, Maayan N, Marshall R, Lutje V, Soares-Weiser K. Anogenital warts: incidence, prevalence, self-reported history and quality of life. London, UK: Cochrane Response. 2016.
25. Ponder BA. Cancer genetics. Nature. 2001;411(6835):336-41.
26. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus genes. 2010;40(1):1-13.
27. Xue J, Vesper BJ, Radosevich JA. Human Papillomavirus: A Brief Overview. HPV and Cancer: Springer; 2012. p. 1-15.
28. Alp AG. Genomic organization and proteins of human papillomavirus. Mikrobiyoloji bulteni. 2012;46(3):507.
29. Bosch FX, Lorincz A, Muñoz N, Meijer C, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of clinical pathology. 2002;55(4):244-65.
30. Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001;20(54):7888-98.
31. Huh K, Zhou X, Hayakawa H, Cho J-Y, Libermann TA, Jin J, et al. Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Cullin 2 Ubiquitin Ligase Complex, Which Contributes to Degradation of the Retinoblastoma Tumor Suppressor. Journal of Virology. 2007;81(18):9737-47.
32. Jabbar SF, Park S, Schweizer J, Berard-Bergery M, Pitot HC, Lee D, et al. Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein. Cancer research. 2012;72(16):4008-16.
33. Miller J, Dakic A, Chen R, Palechor-Ceron N, Dai Y, Kallakury B, et al. HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytes. PLoS Pathog. 2013;9(4):e1003284.
34. Scheffner M, Whitaker NJ, editors. Human papillomavirus-induced carcinogenesis and the ubiquitin–proteasome system. Seminars in cancer biology; 2003: Elsevier.
35. Rasouli E, Shahnavaz Z, Basirun WJ, Rezayi M, Avan A, Ghayour-Mobarhan M, et al. Advancements in electrochemical DNA sensor for detection of human papilloma virus-A review. Analytical biochemistry. 2018;556:136-44.
36. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Meerten ELvP, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. Journal of translational medicine. 2013;11(1):88.
37. Murall CL, Reyné B, Selinger C, Bernat C, Boué V, Grasset S, et al. HPV cervical infections and serological status in vaccinated and unvaccinated women. Vaccine. 2020.
38. Del Prete R, Ronga L, Magrone R, Addati G, Abbasciano A, Di Carlo D, et al. Epidemiological evaluation of human papillomavirus genotypes and their associations in multiple infections. Epidemiology & Infection. 2019;147.
39. Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, et al. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. Journal of biomedical science. 2014;21(1):69.
40. Schiffman M, Doorbar J, Wentzensen N, De Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nature reviews Disease primers. 2016;2(1):1-20.
41. Castle PE, Eaton B, Reid J, Getman D, Dockter J. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology. Journal of clinical microbiology. 2015;53(4):1277-81.
42. Nobbenhuis M, Meijer C, Van Den Brule A, Rozendaal L, Voorhorst F, Risse E, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. British journal of cancer. 2001;84(6):796-801.
43. de Sanjose S, Holme F. What is needed now for successful scale-up of screening? Papillomavirus Research. 2019;7:173-5.
44. Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. The lancet oncology. 2011;12(11):1023-31.
45. Ewaisha R, Panicker G, Maranian P, Unger ER, Anderson KS. Serum immune profiling for early detection of cervical disease. Theranostics. 2017;7(16):3814.
46. Sohrabi A, Mirab-Samiee S, Modarresi MH, Izadimood N, Azadmanesh K, Rahnamaye-Farzami M. Development of in-house multiplex real time PCR for human papillomavirus genotyping in Iranian women with cervical cancer and cervical intraepithelial neoplasia. Asian Pac J Cancer Prev. 2014;15(15):6257-61.
47. Phillips S, Garland SM, Tan JH, Quinn MA, Tabrizi SN. Comparison of the Roche Cobas® 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for detection of high-risk human papillomavirus genotypes in women undergoing treatment for cervical dysplasia. Journal of Clinical Virology. 2015;62:63-5.
48. Lie A, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecologic oncology. 2005;97(3):908-15.
49. Pitts MK, Fox C, Willis J, Anderson J. What do gay men know about human papillomavirus? Australian gay men's knowledge and experience of anal cancer screening and human papillomavirus. Sexually transmitted diseases. 2007;34(3):170-3.
50. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 2014;63(5):1-30.
51. Fait T, Dvořák V, Pilka R. Nine-valent HPV vaccine-new generation of HPV vaccine. Ceska gynekologie. 2015;80(6):397-400.
52. Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, et al. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine. 2017;35(35):4637-45.
53. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert opinion on drug safety. 2015;14(5):697-712.
54. Bouvret P, Mougin C, Pretet J, Meurisse A, Bonnetain F, Fiteni F. Practices and attitudes regarding HPV vaccination among general practitioners from Besançon. Journal de gynecologie, obstetrique et biologie de la reproduction. 2016;45(8):972-8.
55. Oshman LD, Davis AM. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). jama. 2020;323(5):468-9.
56. Ferley J, Bray F, Pisani P, Parkin D. Globocan 2002: Cancer incidence, mortality and prevalence worldwide, IARC Cancerbase. No 5, Version 2.0. Lyon: IARC Press; 2004.
57. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama. 2013;309(17):1793-802.
58. Szarewski A. HPV vaccination and cervical cancer. Current oncology reports. 2012;14(6):559-67.
59. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute. 2004;96(8):604-15.
60. Organization WH. Use of cryotherapy for cervical intraepithelial neoplasia. WHO Geneva; 2011.
61. Organization WH. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention: World Health Organization; 2013.
62. Grabowska AK, Kaufmann AM, Riemer AB. Identification of promiscuous HPV16‐derived T helper cell epitopes for therapeutic HPV vaccine design. International journal of cancer. 2015;136(1):212-24.
63. López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Computational and structural biotechnology journal. 2016;14:58-68.
64. Kim HJ, Kim SY, Lim SJ, Kim JY, Lee SJ, Kim H-J. One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein expression and purification. 2010;70(1):68-74.
65. Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. New biotechnology. 2017;39:174-80.
66. Agency EM. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. 2016.
67. Control CfD, Prevention. Human papillomavirus (HPV) ACIP vaccine recommendations. Series Retrieved from https://www cdc gov/vaccines/hcp/acip-recs/vacc-specific/hpv html. 2016.
68. Cancer ICoESoC. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiology Biomarkers & Prevention. 2009;18(4):1060.
69. Castillejo MM, Beceiro BB, Villanueva MN, Peguera PC, Baquerano MM. Estrategias de prevención del cáncer. Aten Primaria. 2007;39(Supl 3):47-66.
70. Family A. New Findings on Contraceptives. Health. 2008.
71. Al Moustafa A-E, Kassab A, Darnel A, Yasmeen A. High-risk HPV/ErbB-2 interaction on E-cadherin/catenin regulation in human carcinogenesis. Current pharmaceutical design. 2008;14(22):2159-72.
72. Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre‐cancer: Results from the EPIC cohort. International journal of cancer. 2014;135(2):453-66.
73. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. American Journal of Transplantation. 2019;19(11):3202-6.
- Abstract Viewed: 104 times
- pdf Downloaded: 79 times